SCHEMBL14739012

SCHEMBL14739012

Cc1ccc2c(-c3cnc4[nH]cc(C(=O)NC(C)(C)CNC(=O)O)c4n3)n[nH]c2c1

nearest known ligand 0.55

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SYK P43405 20/20 0.55
CYP2D6 P10635 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14738758 0.91 SYK (0.62) SYKCYP2D6
SCHEMBL14738651 0.91 SYK (0.53) SYKCYP2D6
SCHEMBL14751453 0.90 SYK (0.55) SYKCYP2D6
Hydrochloric Acid SCHEMBL14737721 0.90 SYK (0.55) SYKCYP2D6
SCHEMBL14738027 0.89 SYK (0.57) SYKCYP2D6
SCHEMBL14751551 0.87 SYK (0.53) SYKCYP2D6
SCHEMBL14738451 0.86 SYK (0.53) SYKCYP2D6
SCHEMBL14738626 0.85 SYK (0.55) SYKCYP2D6
SCHEMBL14737696 0.84 SYK (0.50) SYKCYP2D6
SCHEMBL14737663 0.82 SYK (0.71) SYKCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2763990-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2017-02-22 EP disclosed
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 US disclosed
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS SYK, ZAP70, JAK1 SYK 1/4885CYP2D6 2796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.